



July 08, 2024

To

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
Tel: 022 - 2272 1233 /4  
Fax: 022 - 22721919

Ref: Aragen Life Sciences Limited

Scrip Code: 973783

ISIN: INE483107010

**Sub: Intimation under Regulation 51(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

The 23<sup>rd</sup> Annual General Meeting (AGM) of the members of the Company was held today, i.e., on Monday, 08<sup>th</sup> July 2024 at 09.00 A.M (IST) at the registered office of the Company, and the shareholders have, inter-alia, approved the following:

1. Mr Manmahesh Kantipudi, Whole-time Director & CEO, who retired by rotation and being eligible offered himself for re-appointment at the AGM, was re-appointed.
2. Dr Robert Richard Ruffolo (DIN: 08404004) was re-appointed as Non-Executive Independent Director for the second term of 5 (five) consecutive years commencing from April 17, 2024 up to April 16, 2029 (both days inclusive), at a remuneration of US\$ 60,000 per annum, (excluding the sitting fees). Further, continuation of Dr Ruffolo as Independent Director notwithstanding his attaining the age of 75 years in 2025 was approved.
3. Mr Ajay Srivastava, the existing non-independent director, was designated as Non-Executive Independent Director for a second term of 5 (five) years commencing from May 14, 2024 up to May 13, 2029 (both days inclusive), at the current remuneration of ₹40,00,000 (Rupees Forty Lakhs Only) per annum (excluding the sitting fees).

Pursuant to Regulation 51 (2) read with Part B of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take this intimation on your records.

**For Aragen Life Sciences Limited**

**Ramakrishna Kasturi**

Company Secretary & Compliance Officer

Registered & Corporate Office  
Aragen Life Sciences Ltd,  
28 A, IDA Nacharam, Hyderabad 500 076, India  
T: +91 40 6692 9999 F: +91 40 6692 9900  
W: aragen.com CIN: U74999TG2000PTC035826